Bionano Genomics, Inc. (BNGO)

Market Cap	13.59M +7.1%
Revenue (ttm)	28.74M +1.0%
Net Income	-31.60M
EPS	-4.21
Shares Out	11.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,299
Open	1.200
Previous Close	1.170
Day's Range	1.200 - 1.238
52-Week Range	1.060 - 5.500
Beta	1.63
Analysts	Buy
Price Target	5.00 (+308.16%)
Earnings Date	May 13, 2026

About BNGO

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 97
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://bionano.com

Financial Performance

In 2025, Bionano Genomics's revenue was $28.51 million, a decrease of -7.37% compared to the previous year's $30.78 million. Losses were -$26.40 million, -76.44% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 308.16% from the latest price.

Price Target

$5.0

(308.16% upside)

Analyst Consensus: Buy